GLP-1
52 articles on GLP-1, written by Shotlee and medically reviewed for clinical accuracy.
New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo
As new weight-loss medications enter the UAE market, patients are questioning insurance coverage. We break down the realities of policy, medical necessity, and the future of metabolic health.
2 min read
Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors
The federal government has extended its commitment to fund GLP-1 obesity medications through 2027, shifting away from private insurer mandates to protect seniors from premium hikes.
2 min read
Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes
A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.
2 min read
GLP-1 Activates KATP Channels in Coronary Pericytes for Cardioprotection
A new study in Nature Communications uncovers how GLP-1 activates ATP-sensitive potassium (KATP) channels in coronary pericytes, providing a novel cardioprotective mechanism through brain-gut-heart signaling. This discovery shifts focus from cardiomyocytes to the microvascular role of pericytes in enhancing myocardial blood flow. Understand the implications for GLP-1 receptor agonists in heart disease treatment.
7 min read
Amanda Bynes New Tattoo After 30-lb Ozempic Weight Loss
Amanda Bynes revealed a striking new tattoo following her 30-pound weight loss with Ozempic. The actress, known for Hairspray and She's the Man, added to her collection at Atomic Tattoo in Hollywood. Her ink symbolizes transformation and friendship amid GLP-1 success.
1 min read
Green Tea Mimics GLP-1 Effects for Weight Loss: Research
A scientific review identifies green tea and other dietary compounds that could replicate GLP-1 inhibitor effects for weight management. Researchers from Heliopolis University highlight potential natural alternatives amid high medication costs and side effects. Experts caution these are not direct substitutes.
2 min read
Wegovy Pill: 18,410 Prescriptions in First Full Week
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its first full week after launch, surpassing other GLP-1 starts. Investors eye its edge over Eli Lilly in the competitive obesity market. Oral treatments offer needle-free flexibility for patients.
1 min read
New Data: Little Weight Rebound After Stopping Ozempic, Wegovy
New research challenges fears of quick weight regain after stopping GLP-1 drugs like Ozempic and Wegovy. Real-world data reveals many patients sustain their losses. Experts say durability is possible without lifelong treatment.
1 min read
Lost 11st on Mounjaro: Simple Trick Beat Plateau
Emilly Murray transformed from 22st 2lbs to a slim 9st using Mounjaro, conquering binge eating and food noise. After hitting a plateau at 11st, she boosted water intake to 2-3 liters daily and increased meat and fish consumption. This simple strategy reignited her weight loss toward her 10st goal.
3 min read
Research: 4p Hot Drink Mimics GLP-1 for Weight Loss
A scientific review shows certain affordable foods and drinks, including a 4p cup of green tea, could mimic GLP-1 inhibitors used in weight loss drugs. These natural compounds may support appetite regulation and blood sugar control. However, experts caution they are not direct alternatives to medications like Ozempic.
2 min read
Celebs Showing 'Ozempic Face' from GLP-1 Weight Loss Drugs
Stars using GLP-1 medications like Ozempic for dramatic weight loss are sparking talk of 'Ozempic face': sunken cheeks, new wrinkles, and sagging skin. Cleveland Clinic endocrinologist Vinni Makin notes this gaunt look stems from rapid fat loss. Public figures face scrutiny as the trend grows.
1 min read
Oxford Study: GLP-1 Weight Regain, Food Matters More
A new University of Oxford study reveals that GLP-1 users regain weight rapidly after stopping medications like Ozempic, with cardiometabolic benefits reversing within two years. This underscores the need for portion-controlled, nutrient-dense foods to maintain satiety on fewer calories. Food innovation will play a key role in supporting former users.
3 min read
Ozempic's Rise: GLP-1 Drugs Curbing US Obesity Rates
CDC 2024 data shows US obesity rates dipping for the first time in decades, thanks to Ozempic and GLP-1 drugs. Originally a diabetes treatment, these medications mimic GLP-1 hormones for dramatic weight loss. Learn the serendipitous science behind them and their broader implications.
2 min read
GLP-1 Drugs Transform More Than Waistlines as Usage Doubles
GLP-1 drugs are revolutionizing more than just waistlines, with nationwide usage doubling rapidly. These medications mimic the gut hormone glucagon-like peptide to signal fullness to the brain and slow gut motility. However, they often trigger GI side effects like nausea and vomiting, especially during dose changes.
1 min read
Seoul Hoards 66% of GLP-1 Supply as High-Risk Areas Lack
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
2 min read
Lupin, Galenicum Sign Semaglutide Deal for 23 Countries
Lupin has signed a licensing and supply agreement with Galenicum for injectable Semaglutide in 23 countries. Galenicum handles development and manufacturing, while Lupin manages approvals and commercialization. This boosts access to the GLP-1 drug for diabetes and obesity treatment.
2 min read
GLP-1 Drugs: Weight Loss Benefits & Fertility Risks for Women
GLP-1 receptor agonists excel in weight management and glucose control, but their effects on women's reproductive health demand attention. These drugs can restore ovulation in obese women with insulin resistance, yet they risk unplanned pregnancies and are unsafe during gestation. Consult experts before use.
3 min read
GLP-1 Drugs Save Airlines $580M Yearly in Fuel Costs
Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.
2 min read
Doctor: You May Regain Weight After Stopping GLP-1 Drugs
Doctor Karan Rajan explains why you might regain weight after quitting GLP-1 drugs: they mimic treatments for chronic conditions like high blood pressure. Obesity requires ongoing management with lifestyle factors like diet, exercise, and sleep. Not everyone needs GLP-1s forever, but stopping without changes risks relapse.
1 min read
Novo Nordisk's 'There's Only One Ozempic' Campaign Reunites Stars
Novo Nordisk introduces the 'There's Only One Ozempic' campaign, reuniting comedy duo Justin Long and John Hodgman to spotlight Ozempic's unique FDA-approved benefits for type 2 diabetes. The effort uses humor and education to distinguish genuine Ozempic (semaglutide) from unapproved compounded versions. It encourages vital conversations between patients and healthcare providers.
5 min read
South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
4 min read
GLP-1 Drugs Risk Bone & Muscle Loss in Menopause
GLP-1 receptor agonists drive effective weight loss but can accelerate bone and muscle loss in postmenopausal women. Aging naturally reduces muscle mass and bone density, and rapid weight loss amplifies these risks. Protect your health with resistance exercise, adequate protein, and comprehensive monitoring.
2 min read
Understanding GLP-1 Drugs for Weight Loss & Diabetes
GLP-1 drugs mimic natural hormones to reduce hunger, slow digestion, and control blood sugar, aiding weight loss and type 2 diabetes. In Malaysia, over 54% of adults are overweight or obese, prompting Health Ministry rollout for vulnerable groups in 2026. Understand benefits, risks, and safe use guidelines.
3 min read
GLP-1 Therapy: Benefits for Metabolic Health
GLP-1 medications extend beyond diabetes and weight loss to enhance overall metabolic health. They improve insulin sensitivity, curb chronic inflammation, and optimize cholesterol levels. Patients often report sustained energy and better wellness.
2 min read
3 Arrested for $16K GLP-1 Drug Robbery at Pharmacy
Three suspects face robbery charges after stealing $16,000 worth of GLP-1 weight loss drugs, including Ozempic, Mounjaro, and Trulicity, from a pharmacy delivery in Bensalem, Pennsylvania. Police quickly apprehended the men from New York following a high-speed chase. The incident highlights surging demand for these popular medications.
1 min read
Prof Urges Caution on Funding Wegovy Rollout
Prof Jim Mann cautions against broad funding for Wegovy, urging focus on high-risk patients like those with heart disease or diabetes. He emphasizes integrating GLP-1 medications into a national obesity strategy with mandatory nutritional support to prevent weight regain. Early data highlights side effect risks and the need for dietary counseling.
2 min read
Specialist: Funding Wegovy Saves Taxpayer Money Long-Term
Pharmac is evaluating funding for Wegovy, a GLP-1 receptor agonist, to combat New Zealand's high obesity rates. Weight loss specialist Dr. Gerard McQuinlan says it could save taxpayers billions by preventing diseases like Type 2 diabetes. Experts weigh long-term costs, side effects, and criteria.
2 min read
Do GLP-1 Drugs Really Balance Ozempic Face and Weight Loss?
GLP-1 medications like Ozempic drive rapid weight loss but often trigger 'Ozempic face'—a gaunt, sagging facial look from fat volume loss. Do these drugs truly balance the effects? Evidence shows they don't selectively protect facial areas; targeted strategies are essential.
1 min read
Ozempic Era Over? BMJ Study on GLP-1 Weight Regain
The Ozempic hype may fade as a BMJ study shows users regain lost weight within 1.5 years after stopping GLP-1 drugs. These medications reduce appetite but require lifelong use and lifestyle changes for lasting results. Obesity stems from systemic issues like convenience culture and ultra-processed foods, not just willpower.
3 min read
Emilly's Mounjaro Journey: Beating Plateau for Lasting Loss
Emilly dropped from 22st to 9st 2lb on Mounjaro by tackling her plateau with more water and protein. Experts reveal why 85% of GLP-1 users stall and share proven strategies to restart progress. Avoid rapid regain by combining drugs with lifestyle changes.
3 min read
GLP-1 Drugs Reshaping Eating Habits in Connecticut
GLP-1 weight-loss drugs like Ozempic and Wegovy are changing how people in Connecticut eat, boosting demand for protein-rich foods to combat muscle loss. Nutrition experts and restaurateurs note shifts toward balanced meals and smaller portions. A clinical epidemiologist reveals how these drugs suppress appetite and delay gastric emptying for significant weight reduction.
4 min read
FDA Expedited Drug Program Raises Safety Concerns for Obesity Meds
The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.
4 min read
Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed
Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.
2 min read
GLP-1s Shift Food Habits: Why It Matters for Agriculture
GLP-1 medications are quietly revolutionizing grocery shopping by reducing appetite and shifting preferences toward high-protein, high-fiber foods. About 12% of North American adults now use these drugs, with numbers set to rise fast. Learn how this affects what we eat and agriculture's future.
2 min read
How to Beat Ozempic Plateau: GLP-1 Expert Tips
Nearly 85% of GLP-1 users hit a weight loss plateau, but experts say simple tweaks can restart progress. From optimizing doses to boosting protein and walking after meals, discover how to turbocharge Ozempic, Wegovy, or Mounjaro. Avoid quitting—stopping leads to rapid regain, per Oxford research.
4 min read
Doctor Shares 4 Foods That Mimic Ozempic for Weight Loss
Mumbai doctor Dr. Manan Vora shares four food categories that mimic Ozempic's appetite-suppressing effects through high fiber, protein, and healthy fats. These natural options boost GLP-1 and PYY hormones, slow digestion, and enhance fullness. Ideal for evidence-based weight management.
2 min read
Novo's Wegovy Oral Pill Shows Strong Early US Momentum vs Lilly
Novo Nordisk's new oral Wegovy pill achieved 3,071 retail prescriptions in its first four days in the US. This strong start signals competition with Eli Lilly's offerings. Analysts predict up to $1 billion in 2024 sales if momentum continues.
1 min read
Med Spas Booming: Safe for GLP-1 Weight Loss?
Med spas offering GLP-1 medications and injectables are everywhere, blending aesthetics with weight management. But varying training and oversight raise safety concerns from infections to counterfeit products. Learn how to vet providers for safe, effective GLP-1 weight loss programs.
4 min read
Heather Gay Sticks with Ozempic GLP-1 for Wellness
Real Housewives star Heather Gay affirms she's not quitting GLP-1 medications like Ozempic. After losing 25 pounds since 2023, she emphasizes feeling energized through protein and fiber, not scale obsession. Her story highlights GLP-1s as part of a mindful wellness shift.
2 min read
Heather Gay: Sticking with GLP-1s After 25-lb Loss
Heather Gay, star of Real Housewives of Salt Lake City, shares her commitment to GLP-1 medications like Ozempic after shedding 25 pounds. She prioritizes how she feels over scale numbers, pairing the drug with Atkins for protein-rich nutrition. Now in her 50s, she feels healthier and more body-confident than ever.
3 min read
Cardiologist: GLP-1 Drugs Benefits Beyond Weight Loss for Heart, Liver
Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.
1 min read
Ozempic Book Reframes Obesity Views in GLP-1 Era
A new book, 'Off the Scales,' reveals how Ozempic and GLP-1 drugs are reshaping societal views on obesity. Author Aimee Donnellan details their development, profound weight loss effects, and the urgent need for medical approaches to this growing crisis. Learn why these therapies mark a turning point in weight management.
2 min read
AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments
AbbVie is bolstering its obesity portfolio with GUBamy, an amylin-based drug from Gubra as a GLP-1 alternative. Unlike gut hormone-mimicking GLP-1s like Wegovy and Zepbound, amylin targets pancreatic hormones for improved tolerability and muscle retention. The company eyes long-term efficacy amid a $150B market boom.
1 min read
Viking Therapeutics Stock Surges on VK2735 Trial Success
Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.
1 min read
GLP-1 Drugs Reshaping Spending on Food and Beauty
Weight loss drugs like GLP-1 medications are transforming consumer spending patterns. New Circana research reveals users cut grocery costs by 2% but increase outlays on beauty and self-care items. Protein-focused products surge 40% as users combat muscle loss side effects.
2 min read
Wegovy Pill in NJ Stores: Where to Get It
The first oral GLP-1 for weight loss, Wegovy pill, is now available in New Jersey stores. One in eight adults have tried GLP-1 meds, with 20% interested per KFF data. Discover where to buy, costs, and safety info.
2 min read
GLP-1 Drugs Reshape Food Economy
GLP-1 medications are revolutionizing not just weight loss but how people approach food, prioritizing protein quality over quantity. Research shows users eat less overall, including less meat, yet value nutrient-dense proteins more highly. These changes signal premiumization in the food sector and broader economic impacts. (~198 chars)
6 min read
Alicia Caiola, NY Medical Weight Loss Expert, Discusses GLP-1 Therapies
A recent article highlights key considerations for individuals seeking qualified medical weight loss providers, particularly concerning GLP-1 treatments. It stresses the importance of thorough evaluations, ongoing monitoring, and comprehensive plans for effective and sustainable weight management.
3 min read
GLP-1s: Understanding the Evolution of Weight-Loss Medications
Weight-loss drugs, particularly those mimicking GLP-1, have gained significant traction. This article delves into their functionality, efficacy, side effects, accessibility challenges, and the emergence of more accessible pill versions.
6 min read
Strategic Acquisitions and Partnerships in the GLP-1 Agonists Market: An Overview of Recent Trends
The global GLP-1 agonists market is anticipated to reach over USD 260.1 billion by 2034, demonstrating a CAGR of 19.9% during the forecast period. This growth is driven by innovations in diabetes, obesity, and cardiovascular disease treatments, though high costs and administration challenges remain.
4 min read
WHO Issues Guidance on GLP-1 Medications for Obesity, Hailing Them as a "Scientific Advance" and "New Era"
The World Health Organization (WHO) has issued new guidelines advocating for the use of GLP-1 drugs in the treatment of obesity. These guidelines suggest that GLP-1 therapies can be used long-term by adults, excluding pregnant women, when combined with intensive behavioral therapy.
3 min read
Revolutionizing Drug Discovery: AI and Peptide Therapy for Longevity
Artificial intelligence is revolutionizing the field of peptide therapy, drastically accelerating drug discovery timelines. This is especially promising for tackling complex diseases like Alzheimer's and advancing the field of longevity research.
3 min read